KLRS

insider transactions

Kalaris Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Cluster buy signal: 2 different insiders made open-market purchases in the last 365 days, totalling $16.2M.

Net shares · 365d

+1.2M

1.3M buy · 90.0K sell

Net value · 365d

$12.2M

$16.2M in · $4.0M out

Sentiment · 365d

Net buying

80% buying · 20% selling

Open-market trades · 365d

1.3M buy · 90.0K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 10, 26

Michael Dybbs

Director

$0

37.0K sh

Own New
Grant·A
Jun 5, 26

Michael Dybbs

Director

$0

10.0K sh

Own New
Grant·A
Jun 4, 26

Srinivas Akkaraju

Director

$0

4.3K sh

Own New
Grant·A
Jun 4, 26

Srinivas Akkaraju

Director

$0

6.8K sh

Own +32%
Grant·A
Jun 3, 26

Leone D Patterson

Director

$0

9.0K sh

Own New
Grant·A
Jun 3, 26

Morana Jovan-Embiricos

Director

$0

9.0K sh

Own New
Grant·A
Jun 3, 26

David Hallal

Director

$0

9.0K sh

Own New
Grant·A
Jun 3, 26

Napoleone Ferrara

Director

$0

9.0K sh

Own New
Grant·A
Jun 3, 26

Michael Dybbs

Director

$0

9.0K sh

Own New
Grant·A
Jun 3, 26

Srinivas Akkaraju

Director

$0

9.0K sh

Own New
Grant·A
Jun 3, 26

Anthony P Adamis

Director

$0

9.0K sh

Own New
Other·J
May 20, 26

Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC

Director, 10% Owner

$0

4.5K sh
Other·J
May 20, 26

Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC

Director, 10% Owner

$0

14.9K sh
Other·J
May 20, 26

Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC

Director, 10% Owner

$0

66.9K sh
Buy·P
May 20, 26

Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC

Director, 10% Owner

$1.2M

244.3K sh · $4.83

Own +12%
Sell·S
Apr 16, 26

David Hallal KEY

Chief Executive Officer

$1.5M

30.6K sh · $49.57

Own -2%
Sell·S
Mar 20, 26

Brett R Hagen

Chief Accounting Officer

$12.9K

1.9K sh · $6.72

Own -100%
Grant·A
Mar 19, 26

Andrew Oxtoby KEY

President and Chief Executive…

$0

222.0K sh

Own New
Grant·A
Mar 19, 26

Matthew Feinsod

Chief Medical Officer

$0

135.0K sh

Own New
Grant·A
Mar 19, 26

Brett R Hagen

Chief Accounting Officer

$0

60.8K sh

Own New
Grant·A
Feb 19, 26

Srinivas Akkaraju

Director, 10% Owner

$0

8.3K sh

Own New
Grant·A
Feb 19, 26

Srinivas Akkaraju

Director, 10% Owner

$0

6.2K sh

Own New
Grant·A
Feb 9, 26

David Hallal KEY

Chief Executive Officer

$0

128.0K sh

Own +8%
Grant·A
Feb 5, 26

Michael Dybbs

Director

$0

27.4K sh

Own New
Sell·S
Jan 13, 26

David Hallal KEY

Chief Executive Officer

$2.5M

57.5K sh · $42.70

Own -4%
Buy·P
Jan 9, 26

Srinivas Akkaraju

Director

$10.0M

588.2K sh · $17.00

Own +46%
Buy·P
Dec 18, 25

Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC

Director, 10% Owner

$5.0M

479.8K sh · $10.42

Own +32%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 10, 2026	Michael Dybbs	Director	Grant A	37.0K	New	—	$0
Jun 5, 2026	Michael Dybbs	Director	Grant A	10.0K	New	—	$0
Jun 4, 2026	Srinivas Akkaraju	Director	Grant A	4.3K	New	—	$0
Jun 4, 2026	Srinivas Akkaraju	Director	Grant A	6.8K	+32%	—	$0
Jun 3, 2026	Leone D Patterson	Director	Grant A	9.0K	New	—	$0
Jun 3, 2026	Morana Jovan-Embiricos	Director	Grant A	9.0K	New	—	$0
Jun 3, 2026	David Hallal	Director	Grant A	9.0K	New	—	$0
Jun 3, 2026	Napoleone Ferrara	Director	Grant A	9.0K	New	—	$0
Jun 3, 2026	Michael Dybbs	Director	Grant A	9.0K	New	—	$0
Jun 3, 2026	Srinivas Akkaraju	Director	Grant A	9.0K	New	—	$0
Jun 3, 2026	Anthony P Adamis	Director	Grant A	9.0K	New	—	$0
May 20, 2026	Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC	Director, 10% Owner	Other J	4.5K	—	—	$0
May 20, 2026	Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC	Director, 10% Owner	Other J	14.9K	—	—	$0
May 20, 2026	Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC	Director, 10% Owner	Other J	66.9K	—	—	$0
May 20, 2026	Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC	Director, 10% Owner	Buy P	244.3K	+12%	$4.83	$1.2M
Apr 16, 2026	David Hallal KEY	Chief Executive Officer	Sell S	30.6K	-2%	$49.57	$1.5M
Mar 20, 2026	Brett R Hagen	Chief Accounting Officer	Sell S	1.9K	-100%	$6.72	$12.9K
Mar 19, 2026	Andrew Oxtoby KEY	President and Chief Executive Officer	Grant A	222.0K	New	—	$0
Mar 19, 2026	Matthew Feinsod	Chief Medical Officer	Grant A	135.0K	New	—	$0
Mar 19, 2026	Brett R Hagen	Chief Accounting Officer	Grant A	60.8K	New	—	$0
Feb 19, 2026	Srinivas Akkaraju	Director, 10% Owner	Grant A	8.3K	New	—	$0
Feb 19, 2026	Srinivas Akkaraju	Director, 10% Owner	Grant A	6.2K	New	—	$0
Feb 9, 2026	David Hallal KEY	Chief Executive Officer	Grant A	128.0K	+8%	—	$0
Feb 5, 2026	Michael Dybbs	Director	Grant A	27.4K	New	—	$0
Jan 13, 2026	David Hallal KEY	Chief Executive Officer	Sell S	57.5K	-4%	$42.70	$2.5M
Jan 9, 2026	Srinivas Akkaraju	Director	Buy P	588.2K	+46%	$17.00	$10.0M
Dec 18, 2025	Srinivas Akkaraju / Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC / Samsara Opportunity Fund, L.P. / Samsara Opportunity Fund GP, LLC	Director, 10% Owner	Buy P	479.8K	+32%	$10.42	$5.0M

About KLRS insider trading

This page tracks insider transactions for Kalaris Therapeutics, Inc. (KLRS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.